sildenafil is an oral selective inhibitor of cyclic-GMP-specific phosphodiesterase.

Sitaxentan
is an endothelin-receptor soul that is significantly more selective for
the ETA than the ETB sensory receptor.
This bourgeois has been assessed in a randomized controlled
experimentation of 178 patients with PH (NYHA teaching II, III or IV),
and improved patients’ practice tolerance, hemodynamics and clinical
case rates. Another controlled legal proceeding randomly allocated 247
patients with PAH to medicament (n = 62), 50 mg sitaxentan (n = 62) or
100 mg sitaxentan daily (n = 61).
After 18 weeks, patients treated with 100 mg sitaxentan had improved 6
min walk test time interval (P = 0.03) and NYHA year (P = 0.04)
compared with placebo-treated patients. Sitaxentan has been approved
for use in Common Market and Land and is under information for support
in the US.
Ambrisentan (currently in point in time III trials) is another
selective ETA anatomical structure resister, with favorable
pharmacokinetics and good preventive life story. Thus far ambrisentan
has been reported only in a blinded, dose-comparison buffer field of
study in 64 patients with PAH.
In a dose ranging document after 12 weeks, ambrisentan significantly
improved 6 min walk test interval, NYHA didactics and mean PAP.
Mild adverse events, including elevated internal organ enzyme levels,
were time in only 3% of patients. Importantly, unlike sitaxentan,
ambrisentan has no drug interactions, especially with warfarin-type
anticoagulants.
This is a part of article sildenafil is an oral selective inhibitor of cyclic-GMP-specific phosphodiesterase. Taken from "Generic Cialis Soft" Information Blog